You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Molika Ashford covers personalized medicine and molecular diagnostics for GenomeWeb.
In two studies at ESMO, researchers demonstrated the ability of combined biomarker approaches to predict the efficacy of immune checkpoint inhibitors.
The program is in its third year monitoring individuals with these mutations to try to detect disease early, understand their risk, and develop preventive treatments.
In its IPO prospectus, the company shared plans to broaden the use of its methylation technology from cancer screening to diagnostics and residual disease monitoring.
The company is using newly raised funds to support a disseminated trial model, which it said will help it keep its plans to finish the study by the end of 2021.
The company has been authorized by the state of New Jersey to provide sequencing-based cancer detection and surveillance using patient-specific ctDNA assays.
The company reported on its development of a deep learning model to predict gene expression of tumors from whole slide images without the need to sequence RNA.
The company was able to ramp up recruitment for its pivotal ECLIPSE trial after hurdles caused a falloff during the earlier months of the COVID-19 pandemic.
The gene expression test retrospectively identified rheumatoid arthritis patients significantly less likely to respond to TNF inhibitor therapy.
The company recently had a second pre-submission with FDA and expects to begin a prospective trial of its test in the second half of this year.
The company recently said it was discontinuing development of its original and only in-house developed assay after a failed clinical validation.
Howard Hughes Medical Institute will be requiring its researchers to publish their work so it is immediately accessible to the public, ScienceInsider writes.
The Huffington Post reports that Francis Collins, the director of the US National Institutes of Health, has urged Americans to recommit to reason.
About 150 million rapid coronavirus tests purchased by the US federal government are to be distributed to nursing homes, colleges, and the states, according to the New York Times.
In Nature this week: multi-omic analysis of Alzheimer's disease brain samples, de novo assembly of a diploid potato, and more.